Long-term complete remission in IgD-myeloma.

Abstract

Long-term complete remission in IgD multiple myeloma (MM) is rare. This case report describes a patient with a stage IIIB IgD-MM, who was treated with conventional melphalan and prednisone chemotherapy. The monoclonal protein disappeared after four cycles and therapy was discontinued after 14 cycles. Re-evaluation after a follow up of more than 8 years demonstrates a continuing complete remission suggesting a cure. This is remarkable, considering that several adverse prognostic factors were present. In addition a concise review on IgD-MM is given.

• Authors: R H H Bemelmans, D W van Toorn, L van Leeuwen, C G Schaar
• Journal: European journal of haematology (Eur J Haematol) Vol. 76 Issue 4 Pg. 339-41 (Apr 2006) ISSN: 0902-4441 [Print] England
• PMID: 16519706 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents
• Antineoplastic Agents, Alkylating
• Immunoglobulin D
• Melphalan
• Prednisone

Topics

• Aged
• Anti-Inflammatory Agents (administration & dosage)
• Antineoplastic Agents, Alkylating (administration & dosage)
• Bone Marrow Cells (metabolism, pathology)
• Humans
• Immunoglobulin D (blood)
• Male
• Melphalan (administration & dosage)
• Multiple Myeloma (blood, drug therapy, pathology)
• Prednisone (administration & dosage)
• Remission Induction (methods)